Mendalur

Active Ingredient:: Levosimendan
Origin:: EU

Mendalur (Levosimendan)

Q: What is Mendalur used for?

Mendalur contains levosimendan, which is used primarily to provide inotropic and vasodilatory support in patients with acute decompensated heart failure. It helps improve cardiac output and relieve symptoms of congestion in adult patients.

Q: How does levosimendan work?

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, increasing contractile force without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac afterload.

Q: What is the usual dose of Mendalur?

The dosing regimen for Mendalur is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the infusion rate and duration according to established guidelines.

Q: Is Mendalur safe during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Q: How do I order Mendalur from GNH India?

To order Mendalur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Mendalur compare with other inotropic agents?

Unlike traditional catecholamine inotropes, levosimendan increases contractility by sensitizing troponin C to calcium and also provides vasodilation. This dual action can result in improved cardiac output with a lower risk of tachyarrhythmias compared with agents such as dobutamine.

Q: What are the storage requirements for Mendalur?

Mendalur should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product, and keep it in the original packaging to maintain stability.

Q: How is Mendalur administered?

Mendalur is given intravenously, typically as an infusion over a prescribed period. Administration is performed by qualified healthcare professionals in a monitored setting, such as a hospital or intensive care unit.

Q: What are the most serious risks associated with Mendalur?

The most serious risks include severe hypotension, myocardial ischemia, and life‑threatening arrhythmias such as ventricular tachycardia or fibrillation. Continuous hemodynamic and ECG monitoring is essential during treatment.

Q: Who should not use Mendalur?

Mendalur is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiac lesions, or known hypersensitivity to levosimendan or any excipients. Caution is also advised in patients with severe renal impairment.

Levosimendan, the active ingredient in Mendalur, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It enhances cardiac contractility and is used in the treatment of acute decompensated heart failure in adult patients.

GNH India supplies Mendalur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Inca-Pharm S.R.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is indicated for conditions involving impaired cardiac function where inotropic support is required.
Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
Chronic severe heart failure (adjunctive): may be used in specialized settings to augment standard therapy.
Cardiogenic shock: provides inotropic and vasodilatory support when conventional agents are insufficient.

How It Works

Levosimendan binds to troponin C in cardiac myocytes, increasing the sensitivity of the contractile apparatus to calcium without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, leading to vasodilation. The combined inotropic and vasodilatory actions improve cardiac output while reducing afterload.

Side Effects

Levosimendan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

Hypotension: drop in blood pressure, especially after infusion start.
Headache: transient, often related to vasodilation.
Nausea or vomiting: gastrointestinal discomfort.
Flushing: warm sensation and reddening of skin.
Arrhythmias: occasional premature beats.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Myocardial ischemia: chest pain or ECG changes.
Life‑threatening arrhythmias: ventricular tachycardia or fibrillation.
Tachycardia: rapid heart rate unresponsive to treatment.
Anaphylactic reactions: rare but possible hypersensitivity.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures.
Monitor blood pressure: watch for hypotension during and after infusion.
Assess cardiac rhythm: continuous ECG monitoring for arrhythmias.
Evaluate renal function: adjust use in severe renal impairment.
Avoid in severe hypotension: contraindicated when systolic BP <90 mmHg.
Use cautiously in the elderly: start at lower infusion rates.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

Concurrent strong vasodilators (e.g., nitroglycerin): risk of profound hypotension.
Other calcium sensitizers: additive inotropic effect may cause cardiac stress.
High‑dose beta‑blockers: may blunt therapeutic response.

Moderate Interactions (Monitor Closely)

Diuretics: monitor electrolytes and volume status.
ACE inhibitors or ARBs: observe blood pressure closely.
Anticoagulants: watch for bleeding if hypotension occurs.

Frequently Asked Questions

Mendalur contains levosimendan, which is used primarily to provide inotropic and vasodilatory support in patients with acute decompensated heart failure. It helps improve cardiac output and relieve symptoms of congestion in adult patients.

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, increasing contractile force without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac afterload.

The dosing regimen for Mendalur is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the infusion rate and duration according to established guidelines.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Mendalur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility by sensitizing troponin C to calcium and also provides vasodilation. This dual action can result in improved cardiac output with a lower risk of tachyarrhythmias compared with agents such as dobutamine.

Mendalur should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product, and keep it in the original packaging to maintain stability.

Mendalur is given intravenously, typically as an infusion over a prescribed period. Administration is performed by qualified healthcare professionals in a monitored setting, such as a hospital or intensive care unit.

The most serious risks include severe hypotension, myocardial ischemia, and life‑threatening arrhythmias such as ventricular tachycardia or fibrillation. Continuous hemodynamic and ECG monitoring is essential during treatment.

Mendalur is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiac lesions, or known hypersensitivity to levosimendan or any excipients. Caution is also advised in patients with severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 03 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.